Richard S. Shames is Chief Medical Officer at Protagonist Therapeutics, Inc (PTGX). They have made 4 open-market trades across 1 company since 2017, most recently 2019-03-01.
CIK 0001675878
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PTGX | 32,021 | $4.6M |
Shares reported on the most recent Form 4, priced at the 2019-03-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PTGX | SELL | 2019-03-01 | 2019-03-04 | $8.03 | $5K | +13.8% | +42.9% | +11.8% |
| PTGX | SELL | 2019-02-06 | 2019-02-08 | $7.74 | $22K | +3.4% | +33.1% | +53.2% |
| PTGX | SELL | 2017-12-22 | 2017-12-27 | $20.50 | $145K | -3.4% | -6.3% | -56.0% |
| PTGX | SELL · 10b5-1 | 2017-10-05 | 2017-10-10 | $19.00 | $38K | -19.9% | -14.3% | -1.0% |
| PTGX | SELL | 2017-09-12 | 2017-09-12 | $14.31 | $106K | +18.2% | +17.5% | +28.1% |
| PTGX | SELL · 10b5-1 | 2017-08-29 | 2017-08-30 | $17.00 | $26K | -12.1% | +7.7% | +16.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.